Gilead Leads Antiviral Therapy Sales: Kalorama
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 01/25/12 -- With combined sales from the top HIV treatment on the market and several other drugs, Gilead Sciences leads the market, according to healthcare market research publisher Kalorama Information, closely followed by Bristol-Myers Squibb, Roche and Merck. Led by growth in , the market for all reached $53 billion in 2011, according to Kalorama Information's new report, "."
Atripla is the company's newest product, launched in July 2006, and it's the leading treatment for HIV. It is a nucleoside analog, part of a highly active antiretroviral therapy (HAART) regimen or "cocktail" that under best conditions can reduce the presence of HIV RNA in the patient's plasma to undetectable levels, thus prolonging survival. Kalorama estimated the product's sales to be $3.2 billion in 2011. Truvada, Viread, and Hepsera are the company's other antiviral drugs. However, the report finds this is a highly competitive market and other brands are competing for market leadership.
"Gilead Sciences will likely remain strong in the market, but other companies are gaining," said Melissa Elder, the report's author. "Baraclude, for instance, has quadrupled in revenues in the past four years."
Bristol-Myers Squibb holds second place in the antiviral drug market, according to Kalorama Information. The company's Baraclude nucleoside analog has grown from $257 million in sales in 2007 to $1.1 billion today. The company's other leading antiviral drugs are Sustiva and Reyataz. Roche holds the third market position overall; the company's key antivirals include Pegasys, Valcyte, and Tamiflu.
GlaxoSmithKline alone accounted for 25% of the antiviral market in 2009, but has since declined due to patent expirations on key products. The company is not inactive, however. In November 2009, GlaxoSmithKline and Pfizer launched ViiV Healthcare, a new company focusing on HIV treatment that combines the strength of both companies' product and development pipelines in the HIV treatment area. For 2011, the new company accounted for one tenth of the antiviral drug market, according to Kalorama.
Of all the anti-infective drug markets that Kalorama has researched in its report, antivirals presented the most growth and competitive activity. This trend is expected to continue for 2011 with half year sales for key products already showing similar increases. Kalorama's report, "," contains more segment market estimates, estimates for revenues by infection treated, and profiles of key companies in the market.
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on , and our .
Please direct all media inquiries to:
Bruce Carlson
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.01.2012 - 11:25 Uhr
Sprache: Deutsch
News-ID 1076475
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Hospitals, Facilities and Providers
Anmerkungen:
Diese Pressemitteilung wurde bisher 138 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Gilead Leads Antiviral Therapy Sales: Kalorama
"
steht unter der journalistisch-redaktionellen Verantwortung von
Kalorama Information (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
